What’s behind new pharma interest in psychedelic treatments

What’s behind new pharma interest in psychedelic treatments

AbbVie’s purchase of Gilgamesh Pharmaceuticals’ psychedelic compound bretisilocin for up to $1.2 billion last month marked the first time a traditional pharma company has bought an investigational psychedelic drug. The deal suggests pharma is getting more comfortable with psychedelic drugs, despite the Food and Drug Administration’s rejection of MDMA last year.  Following the success of…

Read More
New Study Finds Paediatric Patients With Long-Term Conditions Experience Significant Emotional And Psychological Burdens

New Study Finds Paediatric Patients With Long-Term Conditions Experience Significant Emotional And Psychological Burdens

A new study published in the Journal of Affective Disorders looked at comorbidities and emotions of pediatric patients with multiple long-term conditions through social media feedback. “We selected this research topic to address a critical gap in understanding the emotional and psychological burdens experienced by children with MLTCs, a population whose needs are frequently overlooked…

Read More